Experts describes how collaborative molecular screening platforms can help researchers understand the biology of a cancer and support the design and conduct of subsequent confirmatory trials. Collaborative molecular screening platforms offer a high quality integrated infrastructure for efficient screening of patients with cancer for specific molecular alterations. These identified alterations will define target populations for early trials with novel targeted agents.

Source: European solution for effective cancer drug development presented


David Cottle

UBB Owner & Administrator